Compound Semaglutide Tracking App: What Vial-and-Syringe Users Need
5 min read
CEO & Co-Founder of miora. Consumer health growth expert.
Compound semaglutide is the cost-driven alternative to branded Ozempic and Wegovy. It works because the molecule is the same; it is harder to track because the pen is gone and the dose math is on the user. This is the operational tracking protocol for vial-and-syringe semaglutide.
Topics on this page
Compound semaglutide is the same active molecule as Ozempic and Wegovy. Side-effect profile, titration logic, and outcomes are equivalent in well-sourced product.
Reconstitution math is the most common dosing error. Vial mg, reconstitution volume in mL, and units per dose all need to be logged and calculated correctly.
Reconstituted semaglutide has finite stability. Standard guidance is 28-56 days refrigerated; vary by source and bacteriostatic water quality.
Compound semaglutide is the active ingredient in Ozempic and Wegovy delivered through a different supply chain - 503A compounding pharmacies rather than branded manufacturer pens. The cost difference is substantial; in 2026 a 12-week supply of compound semaglutide often runs 60-80% less than equivalent branded product. The tradeoff is that the dose math moves from the pen onto the user. Reconstitution, concentration, units per dose, vial stability, and source variability are now the user's tracking burden. This guide is the operational protocol for getting this right without making it the dominant time cost of the protocol.
The compound is the same molecule; the operational realities are different.
Form factor. Compound semaglutide is dispensed as a freeze-dried (lyophilized) vial, typically 2 mg, 5 mg, or 10 mg per vial. The user reconstitutes with bacteriostatic water, draws the dose with an insulin syringe, and injects subcutaneously. The branded pens, in contrast, are pre-filled at fixed doses (Wegovy 0.25, 0.5, 1.0, 1.7, 2.4 mg per pen).
Concentration. The compounder dispenses both vial and bacteriostatic water. Common reconstitution is 5 mg of semaglutide in 2 mL of bac water, producing 2.5 mg/mL. A 1 mg weekly dose at this concentration is 0.4 mL or 40 units on a U-100 insulin syringe.
Titration. The same titration schedule applies (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly) but each step requires the user to calculate the correct units on the syringe for the current concentration. The math is straightforward but it is done at 7 a.m. before coffee, and the error mode is consistent.
Storage. Lyophilized vials are stable for 18+ months refrigerated. Reconstituted vials are stable for 28-56 days under refrigeration depending on bacteriostatic water and storage conditions.
The reconstitution calculation has three inputs and one output. Inputs: vial total mg, reconstitution volume in mL, target dose in mg. Output: units on a U-100 insulin syringe.
Formula: units = (target dose in mg / (vial mg / reconstitution mL)) × 100
Worked example. 5 mg vial reconstituted with 2 mL of bac water. Concentration = 2.5 mg/mL. Target dose = 1 mg. Volume needed = 0.4 mL = 40 units on a U-100 syringe.
Another example. 10 mg vial reconstituted with 2 mL. Concentration = 5 mg/mL. Target dose = 0.5 mg. Volume needed = 0.1 mL = 10 units.
The failure modes are predictable. Wrong concentration (forgetting which vial size was reconstituted), wrong syringe (U-100 vs U-40 vs tuberculin), wrong dose target (titration step). A tracker that takes the inputs and computes the units eliminates the morning math.
miora's dose calculator handles this. Drop the vial info once at reconstitution ('5 mg in 2 mL'), tell miora the target dose for the current step, and miora confirms the units for the syringe every time you inject. The math is logged with each dose.
Lyophilized semaglutide is stable for 18+ months in the original refrigerated vial. Reconstituted semaglutide has a much shorter stability window. Standard guidance for reconstituted semaglutide:
Refrigerated at 2-8°C: 28 days is the conservative limit; some sources extend to 56 days with bacteriostatic water containing benzyl alcohol.
Room temperature: 28 days maximum; lower if the bacteriostatic water is sterile water without preservative.
Frozen: Not recommended; freeze-thaw cycles can affect the molecule.
Practical implications. A 5 mg vial reconstituted on Day 0 has 5 weekly 1 mg doses available. At one dose per week, the vial is consumed in 5 weeks - just within the 28-day window if doses are timed correctly. A larger vial (10 mg) reconstituted at 5 mg/mL has 10 weekly 1 mg doses, which exceeds the stability window. Users running larger vials often reconstitute partial volumes or plan for some product loss.
miora's inventory log tracks reconstitution date alongside vial info. Each dose draws against the reconstitution window; if a vial approaches the stability limit with product remaining, miora flags it in the morning summary so the user can plan accordingly.
Compounded semaglutide quality varies by pharmacy, by lot, and sometimes by reconstitution batch. The molecule is the same when manufactured correctly; the manufacturing quality is not uniform across the 503A compounding sector. Source logging is a forward-protection practice in case a side-effect signal emerges.
What to log with each new vial:
Pharmacy name. Which compounder dispensed the product.
Lot number. If provided on the vial label.
Dispensing date. When the vial left the pharmacy.
Vial mg and reconstitution recommendation. Some pharmacies dispense with specific reconstitution instructions.
Bacteriostatic water source and type. Whether it includes benzyl alcohol as preservative.
Reconstitution date. When you reconstituted.
Concentration. The mg/mL produced.
If a side-effect pattern emerges - unusual injection-site reactions, an off-flavor odor, sterility concerns - the source log lets you cross-reference whether the pattern correlates with a specific batch or pharmacy. miora's inventory log captures all of these fields by default for compound product.
The active ingredient is the same molecule, and the side-effect profile is the same. Compound semaglutide users get the same nausea curve, fatigue pattern, GI changes, and mood drift as Wegovy users. The daily six-dimension rubric applies identically.
Two minor considerations specific to compound. First, injection-site reactions may be slightly more common with vial-and-syringe than with auto-pen due to needle angle and technique variability. Most users develop good technique within a few injections; persistent site reactions warrant either a technique check or a clinician conversation about whether the compound batch is producing the issue.
Second, dose precision is slightly worse with insulin syringe than with auto-pen, particularly at small doses. A 10-unit dose drawn manually has more variability than a 0.25 mg auto-pen dose. The variability is small but real. For most users it does not change the protocol; for users very sensitive to side effects, it may explain why one week's curve differs from another.
The daily flow combines the standard GLP-1 daily check with the compound-specific dose log.
At reconstitution: One text: 'reconstituted 5 mg semaglutide vial in 2 mL bac water, [pharmacy], lot #12345, today.' miora logs the vial, calculates concentration, and notes the stability window (e.g., 'stable until 2026-06-12').
At injection: One text: 'injected 1 mg semaglutide, 40 units, left thigh, 8 a.m.' miora confirms the math (40 units at 2.5 mg/mL = 1 mg), decrements the inventory, and notes the next planned injection.
Daily check evening: 'sem check day N: nausea 2 / fatigue 2 / GI fine / 64 oz / 105 g / weight 195.3.' Same as branded. miora parses and logs.
Weekly summary: Side-effect curve mapped to injection day, smoothed weight, protein and hydration trends, plus inventory status (e.g., 'current vial has 3 doses remaining and 11 days of stability'). The compound-specific data is integrated, not separate.
Most flags are the same as branded semaglutide. A few compound-specific additions:
New or persistent injection-site reaction. Technique check first; if reactions persist after technique adjustment, source variability is a possibility. Flag to clinician.
Unexpected potency shift between vials. If side-effect curve at the same dose changes dramatically between a new vial and the previous one, source variability may be involved. Document and flag.
Sterility concerns. Unusual odor, color change, particulate matter in the reconstituted vial. Do not inject; contact the pharmacy.
Pharmacy supply issues. Order delays, batch substitutions, communication shifts. See the compounder shutdown guide for the operational response.
For all other flags - mood drift, protein intake, smoothed weight stall, cardiometabolic signals - the thresholds are the same as branded semaglutide.
Three boundaries.
This guide does not recommend compound semaglutide over branded product. The choice between Wegovy or Ozempic and a compound version is a clinician conversation that depends on cost, insurance coverage, indication, and individual circumstances. miora does not endorse either path.
This guide does not recommend specific compounding pharmacies. Quality varies across the 503A sector; the choice of pharmacy belongs with your prescriber's recommendation or your due diligence, not with miora.
This guide does not source compound semaglutide. miora does not source any compound. References to compounded use are descriptive, not endorsements. This content is for informational purposes only and is not medical advice. Compound semaglutide requires a prescription. Clinician supervision is required regardless of source.
110
